Sign In
Buy IONS
$73.82
+0.85 (+1.16%)
At Close: Jun 03, 2026
Allene Diaz Sells 54,878 Shares of Ionis Pharmaceuticals (NASDAQ:IONS) Stock
05:34am, Saturday, 07'th Mar 2026
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS - Get Free Report) Director Allene Diaz sold 54,878 shares of Ionis Pharmaceuticals stock in a transaction that occurred on Tuesday, March 3rd. The stock was
DCF Advisers LLC Has $7.09 Million Stock Holdings in Ionis Pharmaceuticals, Inc. $IONS
05:34am, Saturday, 07'th Mar 2026
DCF Advisers LLC lifted its holdings in shares of Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) by 18.2% in the third quarter, according to the company in its most recent filing with the Securities and E
Biogen to Share New SMA Data at Muscular Dystrophy Association and SMA Europe Conferences
07:30am, Thursday, 05'th Mar 2026
Long-term data from DEVOTE/ONWARD studies show benefits of high dose nusinersen in people living with spinal muscular atrophy (SMA) New Phase 1b data further illustrate potential of salanersen in SMA,
Ionis Pharmaceuticals, Inc. (IONS) Presents at TD Cowen 46th Annual Health Care Conference Transcript
01:27pm, Monday, 02'nd Mar 2026
Ionis Pharmaceuticals, Inc. (IONS) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Ionis Pharmaceuticals, Inc. $IONS Shares Bought by Artisan Partners Limited Partnership
04:27am, Saturday, 28'th Feb 2026
Artisan Partners Limited Partnership grew its holdings in shares of Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) by 150.8% in the undefined quarter, according to the company in its most recent 13F filin
Ionis to present new data supporting DAWNZERA™ (donidalorsen) in hereditary angioedema at 2026 AAAAI Annual Meeting
07:00am, Friday, 27'th Feb 2026
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced new data to be presented for DAWNZERA™ (donidalorsen), the first and only RNA-targeted medicine for here
Ionis Pharmaceuticals: Digesting Recent Events
02:54am, Friday, 27'th Feb 2026
Ionis Pharmaceuticals recently raised Tryngolza's peak revenue estimate to over $2 billion after strong sHTG data, which has triggered a large stock rally since September 2025. IONS projects over $4 b
Ionis Pharmaceuticals, Inc. (IONS) Presents at Oppenheimer 36th Annual Healthcare Life Sciences Conference Transcript
04:57pm, Thursday, 26'th Feb 2026
Ionis Pharmaceuticals, Inc. (IONS) Presents at Oppenheimer 36th Annual Healthcare Life Sciences Conference Transcript
Ionis Q4 Earnings & Sales Beat, Stock Down on Soft 2026 Outlook
10:21am, Thursday, 26'th Feb 2026
IONS beats Q4 estimates on strong Tryngolza sales, but shares slip 5% as 2026 revenue outlook and slower uptake for new drugs weigh on sentiment.
Olezarsen sNDA accepted by the FDA for Priority Review for the treatment of severe hypertriglyceridemia (sHTG)
07:00am, Thursday, 26'th Feb 2026
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental New Dru
Ionis Pharmaceuticals (IONS) Reports Q4 Earnings: What Key Metrics Have to Say
01:30pm, Wednesday, 25'th Feb 2026
The headline numbers for Ionis Pharmaceuticals (IONS) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wal
Ionis Pharmaceuticals (IONS) Reports Q4 Loss, Tops Revenue Estimates
01:15pm, Wednesday, 25'th Feb 2026
Ionis Pharmaceuticals (IONS) came out with a quarterly loss of $1.14 per share versus the Zacks Consensus Estimate of a loss of $1.21. This compares to a loss of $0.66 per share a year ago.
Ionis Pharmaceuticals, Inc. (IONS) Q4 2025 Earnings Call Transcript
12:57pm, Wednesday, 25'th Feb 2026
Ionis Pharmaceuticals, Inc. (IONS) Q4 2025 Earnings Call Transcript
Ionis Guides Below 2026 Sales Views Despite Strong Growth From Lead Drug
12:48pm, Wednesday, 25'th Feb 2026
Ionis Pharmaceuticals Inc. (NASDAQ: IONS) on Wednesday reported a fourth quarter adjusted loss of $1.15, better than the Wall Street loss estimate of $1.32
Ionis reports fourth quarter and full year 2025 financial results and highlights progress on key programs
07:00am, Wednesday, 25'th Feb 2026
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the “Company”) today reported financial results and provided key updates for the fourth quarter and year ended Decemb
